Spotlight Innovation

Spotlight Innovation Inc. acquires and develops proprietary therapies to address unmet medical needs. (RTs/MTs do not imply endorsements.) $STLT

[Spotlight Innovation @SpotlightInno]

Rare diseases are not so rare: there are 7,000 rare disorders that combined affect 30 million Americans – 1 in 10 of us – and more than half are children. https://t.co/wk4gvdCobH

[Spotlight Innovation @SpotlightInno]

A life-altering diagnosis can be crushing but Jordan is a reminder that you can't stop living during cancer. https://t.co/aJ6CCgVzZv

[Spotlight Innovation @SpotlightInno]

Parents with a chronically ill child are typically very strong but even words said in kindness can hurt. https://t.co/8gBAAkVYGg

[Spotlight Innovation @SpotlightInno]

After a 26-year absence, the primary mosquito that transmits Zika virus, yellow fever and other flaviviruses has been found in Alabama. We're working on a solution! https://t.co/4PpjMjqpzN

[Spotlight Innovation @SpotlightInno]

Using smartphones and ingestible micro-bio-electronic devices can make certain diagnosis much easier. https://t.co/LXVc7gQYyR

[Spotlight Innovation @SpotlightInno]

Chronic pain affects nearly 100 million Americans but what does that mean? https://t.co/eTSaSdIOXb

[Spotlight Innovation @SpotlightInno]

There may be no scientific evidence that a person's attitude improves cancer treatments but it can effect mental state and quality of life. https://t.co/4ftws6fd0A

[Spotlight Innovation @SpotlightInno]

Rare diseases affect more Canadians than all cancers combined, diabetes or cardiovascular disease. Canada has no legal framework for the development of orphan therapies — unlike the United States, which adopted the Orphan Drug Act in 1983. https://t.co/bTL7hZasWy

[Spotlight Innovation @SpotlightInno]

For many, the acronym "SMA" may be foreign. But for parents of a child with spinal muscular atrophy, a rare but deadly genetic disorder, it is all too real. https://t.co/gPK1CbW0Zr

[Spotlight Innovation @SpotlightInno]

Cure SMA has a stringent process for determining how to fund research. The news that our research collaborator, Prof. Ken Hodgetts, received a $300,000 grant to move forward on LDN-5178, for which we hold exclusive rights, is truly a breakthrough. https://t.co/XSVELGm9Vl